期刊
JOURNAL OF RHEUMATOLOGY
卷 39, 期 8, 页码 1533-1538出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.111522
关键词
RHEUMATOID ARTHRITIS; ETANERCEPT; PHARMACOLOGICAL BIOMARKER
类别
资金
- Pfizer (France)
- French Society of Rheumatology
Objective. For patients with rheumatoid arthritis (RA), recommendations are inconclusive about whether tumor necrosis factor-alpha (TNF-alpha)-blocker therapy should be evaluated at 3 or 6 months. Biomarkers are needed to predict at 3 months which patients would benefit from further treatment because of nonoptimal response. Our objective was to investigate whether serum etanercept (ETN) concentrations and anti-ETN antibodies at 3 months are predictors of clinical response to ETN at 6 months in patients with RA in terms of European League Against Rheumatism criteria and Disease Activity Score in 28 joints (DAS28). Methods. Between 2009 and 2010, we included 19 women with active RA who were candidates for ETN therapy. Response criteria were evaluated at 3 and 6 months. Serum concentrations of ETN and anti-ETN antibodies were measured by ELISA at baseline and at 3 and 6 months. Results. Eighteen patients completed followup. Three-month ETN concentrations were lower for 6-month nonresponders than responders (p = 0.03). Three-month ETN levels correlated significantly with change in DAS28 between baseline and 6 months (r = -0.62, p = 0.006). The best predictor of response at 6 months was observed with an ETN threshold of 3.1 mu g/ml at 3 months. No anti-ETN antibodies were found. Conclusion. ETN concentrations at 3 months predict response to ETN therapy at 6 months. Low ETN concentrations could explain the absence of response to ETN, suggesting that patients with low ETN levels could benefit from increased ETN dose or earlier interruption of treatment. (First Release July 1 2012; J Rheumatol 2012;39:1533-8; doi:10.3899/jrheum.111522)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据